UB Paderborn / Katalog / Suche / in CDI

Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System: Lessons From a Tick Salivary Protein

Circulation (New York, N.Y.), 2013-07, Vol.128 (3), p.254-266

2013

Volltextzugriff (PDF)

Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

Journal of innate immunity, 2023-01, Vol.15 (1), p.16-36

2023

Volltextzugriff (PDF)

Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma

Proceedings of the National Academy of Sciences - PNAS, 2010-05, Vol.107 (20), p.9083-9087

2010

Volltextzugriff (PDF)

A FRET-based assay for the quantitation of the thrombin-factor XI interaction

Thrombosis research, 2022-06, Vol.214, p.23-28

2022

Volltextzugriff (PDF)

Thrombin activation of the factor XI dimer is a multistaged process for each subunit

Journal of thrombosis and haemostasis, 2024-05, Vol.22 (5), p.1336-1346

2024

Volltextzugriff (PDF)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen

Journal of thrombosis and haemostasis, 2022-11, Vol.20 (11), p.2538-2549

2022

Volltextzugriff (PDF)

Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B

Thrombosis and haemostasis, 2011-10, Vol.106 (4), p.609

2011

Volltextzugriff (PDF)

A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function

Blood, 2015-03, Vol.125 (11), p.1822-1825

2015

Volltextzugriff (PDF)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa

Journal of thrombosis and haemostasis, 2019-12, Vol.17 (12), p.2047-2055

2019

Volltextzugriff (PDF)

β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Blood, 2010-08, Vol.116 (8), p.1336-1343

2010

Volltextzugriff (PDF)

Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI

Thrombosis and haemostasis, 2018-02, Vol.118 (2), p.340

2018

Volltextzugriff (PDF)

proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking

The FASEB journal, 2009-05, Vol.23 (5), p.1584-1595

2009

Volltextzugriff (PDF)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation

Journal of thrombosis and haemostasis, 2021-07, Vol.19 (7), p.1697-1708

2021

Volltextzugriff (PDF)

Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model

Thrombosis and haemostasis, 2013-11, Vol.110 (5), p.1065

2013

Volltextzugriff (PDF)

Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor

The Journal of biological chemistry, 2004-02, Vol.279 (8), p.6620-6628

2004

Volltextzugriff (PDF)

The Design and Characterization of Receptor-selective APRIL Variants

The Journal of biological chemistry, 2012-10, Vol.287 (44), p.37434-37446

2012

Volltextzugriff (PDF)

Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein I

Thrombosis and haemostasis, 2011-12, Vol.106 (6), p.1069

2011

Volltextzugriff (PDF)

β2‐Glycoprotein I is incorrectly named apolipoprotein H

Journal of thrombosis and haemostasis, 2009-01, Vol.7 (1), p.235-236

2009

Volltextzugriff (PDF)

beta(2)-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Blood, 2010-08, Vol.116 (8), p.1336

2010

Volltextzugriff (PDF)

Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains

Thrombosis and haemostasis, 2000-12, Vol.84 (6), p.1005

2000

Volltextzugriff (PDF)

The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization andcross‐linking

The FASEB journal, 2009-05, Vol.23 (5), p.1584-1595

2009

Volltextzugriff (PDF)

Protein C Inhibitor May Modulate Human Sperm-Oocyte Interactions1

Biology of reproduction, 1998-03, Vol.58 (3), p.670-677

1998

Volltextzugriff (PDF)

Beta2-glycoprotein I is incorrectly named apolipoprotein H

Journal of thrombosis and haemostasis, 2009-01, Vol.7 (1), p.235-236

2009

Volltextzugriff (PDF)

Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Blood, 2010-08, Vol.116 (8), p.1336-1343

2010

Volltextzugriff (PDF)

Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340 and miRNA624

PloS one, 2011-10, Vol.6 (10), p.e25946-e25946

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System: Lessons From a Tick Salivary Protein

Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma

A FRET-based assay for the quantitation of the thrombin-factor XI interaction

Thrombin activation of the factor XI dimer is a multistaged process for each subunit

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen

Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B

A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa

β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI

proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation

Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model

Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor

The Design and Characterization of Receptor-selective APRIL Variants

Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein I

β2‐Glycoprotein I is incorrectly named apolipoprotein H

beta(2)-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains

The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization andcross‐linking

Protein C Inhibitor May Modulate Human Sperm-Oocyte Interactions1

Beta2-glycoprotein I is incorrectly named apolipoprotein H

Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340 and miRNA624

Suchergebnisse filtern